BioHarvest Sciences (NASDAQ:BHST) Shares Down 0.7% - Here's What Happened

Key Points

• BioHarvest Sciences shares slipped 0.7% in Thursday trading, falling as low as $2.76 before last trading at $2.83. Volume jumped to 52,994 shares, well above its average session volume.
• Weiss Ratings downgraded the stock from “sell (e+)” to “sell (d-)” on Thursday, while MarketBeat data still shows a consensus rating of “Hold” and an average target price of $10.00.
• The company’s latest earnings beat expectations with EPS of -$0.11 versus an expected -$0.13, and revenue of $8.51 million slightly topping estimates. However, BioHarvest remains unprofitable, with a negative net margin and return on equity.

BioHarvest Sciences Inc. (NASDAQ:BHST - Get Free Report) was down 0.7% during mid-day trading on Thursday . The company traded as low as $2.76 and last traded at $2.83. 52,994 shares traded hands during trading, an increase of 79% from the average session volume of 29,619 shares. The stock had previously closed at $2.85.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised BioHarvest Sciences from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, June 18th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $10.00.

BioHarvest Sciences Trading Down 0.7%

The business's 50-day moving average is $3.33 and its two-hundred day moving average is $4.17. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.44 and a current ratio of 2.96. The stock has a market capitalization of $55.52 million, a PE ratio of -4.80 and a beta of 0.87.

BioHarvest Sciences (NASDAQ:BHST - Get Free Report) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. BioHarvest Sciences had a negative net margin of 32.54% and a negative return on equity of 76.03%. The company had revenue of $8.51 million for the quarter, compared to analysts' expectations of $8.50 million. As a group, equities research analysts anticipate that BioHarvest Sciences Inc. will post -0.45 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Virtu Financial LLC acquired a new stake in BioHarvest Sciences in the fourth quarter valued at about $60,000. Geode Capital Management LLC acquired a new position in BioHarvest Sciences during the 4th quarter worth approximately $61,000. HRT Financial LP acquired a new position in BioHarvest Sciences during the 4th quarter worth approximately $75,000. Marshall Wace LLP acquired a new position in BioHarvest Sciences during the 4th quarter worth approximately $110,000. Finally, Silverberg Bernstein Capital Management LLC purchased a new position in shares of BioHarvest Sciences during the 1st quarter worth approximately $113,000.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company's product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.